Published in Hum Genet on April 24, 2004
Genome-wide association study confirms SNPs in SNCA and the MAPT region as common risk factors for Parkinson disease. Ann Hum Genet (2010) 4.26
Comprehensive association testing of common mitochondrial DNA variation in metabolic disease. Am J Hum Genet (2006) 2.60
Recent advances in the genetics of Parkinson's disease. Annu Rev Genomics Hum Genet (2011) 2.29
Haplogroup effects and recombination of mitochondrial DNA: novel clues from the analysis of Leber hereditary optic neuropathy pedigrees. Am J Hum Genet (2006) 1.95
Mitochondrial defects and oxidative stress in Alzheimer disease and Parkinson disease. Free Radic Biol Med (2012) 1.67
Mitochondrial dysfunction in the limelight of Parkinson's disease pathogenesis. Biochim Biophys Acta (2008) 1.35
Mitochondrial DNA, base excision repair and neurodegeneration. DNA Repair (Amst) (2008) 1.27
Maternal transmission of Alzheimer's disease: prodromal metabolic phenotype and the search for genes. Hum Genomics (2010) 1.12
Genetic findings in Parkinson's disease and translation into treatment: a leading role for mitochondria? Genes Brain Behav (2007) 1.07
The role of mitochondria in neurodegenerative diseases. J Neurol (2011) 1.05
Mutational screening of the mortalin gene (HSPA9) in Parkinson's disease. J Neural Transm (Vienna) (2009) 0.93
The role of mitochondrial haplogroups in primary open angle glaucoma. Br J Ophthalmol (2006) 0.92
Mitochondrial DNA sequence variation and neurodegeneration. Hum Genomics (2008) 0.91
Role and treatment of mitochondrial DNA-related mitochondrial dysfunction in sporadic neurodegenerative diseases. Curr Pharm Des (2011) 0.90
Shared mechanisms of neurodegeneration in Alzheimer's disease and Parkinson's disease. Biomed Res Int (2014) 0.88
Maternal inheritance and mitochondrial DNA variants in familial Parkinson's disease. BMC Med Genet (2010) 0.87
Mitochondria-wide association study of common variants in osteoporosis. Ann Hum Genet (2011) 0.87
Mitochondrial DNA haplogroups in early-onset Alzheimer's disease and frontotemporal lobar degeneration. Mol Neurodegener (2010) 0.86
Mitochondrial dysfunction in Parkinson's disease: pathogenesis and neuroprotection. Parkinsons Dis (2010) 0.86
mtDNA haplogroup and single nucleotide polymorphisms structure human microbiome communities. BMC Genomics (2014) 0.86
Mitochondrial genomics and CD4 T-cell count recovery after antiretroviral therapy initiation in AIDS clinical trials group study 384. J Acquir Immune Defic Syndr (2011) 0.85
What's to like about the prion-like hypothesis for the spreading of aggregated α-synuclein in Parkinson disease? Prion (2013) 0.85
May "mitochondrial eve" and mitochondrial haplogroups play a role in neurodegeneration and Alzheimer's disease? Int J Alzheimers Dis (2011) 0.83
A generalized model to estimate the statistical power in mitochondrial disease studies involving 2×k tables. PLoS One (2013) 0.83
Does mitochondrial DNA play a role in Parkinson's disease? A review of cybrid and other supportive evidence. Antioxid Redox Signal (2011) 0.83
Do somatic mitochondrial DNA mutations contribute to Parkinson's disease? Parkinsons Dis (2011) 0.82
Specific polymorphic variation in the mitochondrial genome and increased in-hospital mortality after severe trauma. Ann Surg (2007) 0.81
Female genetic distribution bias in mitochondrial genome observed in Parkinson's Disease patients in northern China. Sci Rep (2015) 0.80
Mitochondrial DNA polymorphisms and the risk of Parkinson's disease in Taiwan. J Neural Transm (Vienna) (2007) 0.79
Mitochondrial haplogroups modify the effect of black carbon on age-related cognitive impairment. Environ Health (2014) 0.78
Mitochondrial DNA sequence variation is largely conserved at birth with rare de novo mutations in neonates. Am J Obstet Gynecol (2015) 0.76
Variations of mitochondrial DNA polymerase γ in patients with Parkinson's disease. J Neurol (2013) 0.75
Mitochondria-Derived Damage-Associated Molecular Patterns in Neurodegeneration. Front Immunol (2017) 0.75
Statistical method for testing the neutral mutation hypothesis by DNA polymorphism. Genetics (1989) 73.50
On the number of segregating sites in genetical models without recombination. Theor Popul Biol (1975) 60.96
PAML: a program package for phylogenetic analysis by maximum likelihood. Comput Appl Biosci (1997) 45.07
Statistical tests of neutrality of mutations. Genetics (1993) 24.94
Statistical tests of neutrality of mutations against population growth, hitchhiking and background selection. Genetics (1997) 20.93
Estimating synonymous and nonsynonymous substitution rates under realistic evolutionary models. Mol Biol Evol (2000) 13.01
Mitochondrial genome variation and the origin of modern humans. Nature (2000) 11.92
Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nat Neurosci (2000) 10.62
Properties of statistical tests of neutrality for DNA polymorphism data. Genetics (1995) 7.62
Classification of European mtDNAs from an analysis of three European populations. Genetics (1996) 6.28
Mitochondrial complex I deficiency in Parkinson's disease. J Neurochem (1990) 4.03
Statistical tests of selective neutrality in the age of genomics. Heredity (Edinb) (2001) 3.64
Mitochondrial polymorphisms significantly reduce the risk of Parkinson disease. Am J Hum Genet (2003) 3.39
Phylogenetic network for European mtDNA. Am J Hum Genet (2001) 3.26
1994 William Allan Award Address. Mitochondrial DNA variation in human evolution, degenerative disease, and aging. Am J Hum Genet (1995) 3.22
Abnormalities of the electron transport chain in idiopathic Parkinson's disease. Ann Neurol (1989) 3.11
Mitochondrial DNA variation in human evolution and disease. Gene (1999) 2.72
Inhibition of NADH-linked oxidation in brain mitochondria by 1-methyl-4-phenyl-pyridine, a metabolite of the neurotoxin, 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine. Life Sci (1985) 2.70
Human mtDNA haplogroups associated with high or reduced spermatozoa motility. Am J Hum Genet (2000) 2.64
Mitochondrial genotype associated with longevity. Lancet (1998) 2.58
Does nonneutral evolution shape observed patterns of DNA variation in animal mitochondrial genomes? Annu Rev Genet (2001) 2.46
Mitochondrial DNA variants observed in Alzheimer disease and Parkinson disease patients. Genomics (1993) 2.39
Parkinson's Disease Society Brain Bank, London: overview and research. J Neural Transm Suppl (1993) 2.27
Origin and functional consequences of the complex I defect in Parkinson's disease. Ann Neurol (1996) 2.22
The epidemiology of pathogenic mitochondrial DNA mutations. Ann Neurol (2000) 2.20
Mitochondrial oxidative phosphorylation defects in Parkinson's disease. Ann Neurol (1991) 2.06
Type 2 diabetes is associated with a common mitochondrial variant: evidence from a population-based case-control study. Hum Mol Genet (2002) 1.87
Transmembrane topology of the NuoL, M and N subunits of NADH:quinone oxidoreductase and their homologues among membrane-bound hydrogenases and bona fide antiporters. Biochim Biophys Acta (2002) 1.61
Apoptosis in Parkinson's disease: signals for neuronal degradation. Ann Neurol (2003) 1.55
Mitochondrial DNA transmission of the mitochondrial defect in Parkinson's disease. Ann Neurol (1998) 1.32
Cortical Lewy body pathology in the diagnosis of dementia. Acta Neuropathol (2001) 1.31
Human mitochondrial complex I in health and disease. Am J Hum Genet (1999) 1.23
Phylogenetic network and physicochemical properties of nonsynonymous mutations in the protein-coding genes of human mitochondrial DNA. Mol Biol Evol (2003) 1.19
mt4216C variant in linkage with the mtDNA TJ cluster may confer a susceptibility to mitochondrial dysfunction resulting in an increased risk of Parkinson's disease in the Irish. Exp Gerontol (2003) 1.09
Familial multisystem degeneration with parkinsonism associated with the 11778 mitochondrial DNA mutation. Neurology (1999) 1.05
Mitochondrial DNA mutations in complex I and tRNA genes in Parkinson's disease. Neurology (2000) 1.04
Matrilineal inheritance of complex I dysfunction in a multigenerational Parkinson's disease family. Ann Neurol (1998) 1.04
Sequence analysis of the entire mitochondrial genome in Parkinson's disease. Biochem Biophys Res Commun (2002) 0.91
Increased variation in mtDNA in patients with familial sensorineural hearing impairment. Hum Genet (2003) 0.85
Parkinson disease: analysis of mitochondrial DNA in monozygotic twins. Neurogenetics (2000) 0.78
Atypical parkinsonism in a family of Portuguese ancestry: absence of CAG repeat expansion in the MJD1 gene. Neurology (1997) 0.75
Genome-wide association study identifies novel breast cancer susceptibility loci. Nature (2007) 29.23
Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease. Nat Genet (2009) 14.86
Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. Nat Genet (2011) 9.23
Large-scale genotyping identifies 41 new loci associated with breast cancer risk. Nat Genet (2013) 8.24
A common coding variant in CASP8 is associated with breast cancer risk. Nat Genet (2007) 7.35
Newly discovered breast cancer susceptibility loci on 3p24 and 17q23.2. Nat Genet (2009) 7.30
Heterogeneity of breast cancer associations with five susceptibility loci by clinical and pathological characteristics. PLoS Genet (2008) 6.22
Common variants at 7p21 are associated with frontotemporal lobar degeneration with TDP-43 inclusions. Nat Genet (2010) 5.52
Protective variant for hippocampal atrophy identified by whole exome sequencing. Ann Neurol (2015) 5.10
Breast-cancer risk in families with mutations in PALB2. N Engl J Med (2014) 4.97
A recurrent mutation in PALB2 in Finnish cancer families. Nature (2007) 4.64
Associations of breast cancer risk factors with tumor subtypes: a pooled analysis from the Breast Cancer Association Consortium studies. J Natl Cancer Inst (2010) 4.54
Risk score for the prediction of dementia risk in 20 years among middle aged people: a longitudinal, population-based study. Lancet Neurol (2006) 4.54
Obesity and vascular risk factors at midlife and the risk of dementia and Alzheimer disease. Arch Neurol (2005) 4.49
Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. Nat Genet (2013) 4.35
CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer's disease. Brain (2006) 3.95
Leisure-time physical activity at midlife and the risk of dementia and Alzheimer's disease. Lancet Neurol (2005) 3.95
Genome-wide association studies identify four ER negative-specific breast cancer risk loci. Nat Genet (2013) 3.81
Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study. Lancet Neurol (2009) 3.65
Association of plasma clusterin concentration with severity, pathology, and progression in Alzheimer disease. Arch Gen Psychiatry (2010) 3.64
A common variant at the TERT-CLPTM1L locus is associated with estrogen receptor-negative breast cancer. Nat Genet (2011) 3.37
Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain. Arch Neurol (2009) 3.34
Genome-wide association analysis identifies three new breast cancer susceptibility loci. Nat Genet (2012) 3.20
Fast and robust multi-atlas segmentation of brain magnetic resonance images. Neuroimage (2009) 3.13
Parkinsonism, premature menopause, and mitochondrial DNA polymerase gamma mutations: clinical and molecular genetic study. Lancet (2004) 2.91
Risk of estrogen receptor-positive and -negative breast cancer and single-nucleotide polymorphism 2q35-rs13387042. J Natl Cancer Inst (2009) 2.88
Low penetrance breast cancer susceptibility loci are associated with specific breast tumor subtypes: findings from the Breast Cancer Association Consortium. Hum Mol Genet (2011) 2.72
Hippocampus and entorhinal cortex in mild cognitive impairment and early AD. Neurobiol Aging (2004) 2.49
Apolipoprotein E epsilon4 allele, elevated midlife total cholesterol level, and high midlife systolic blood pressure are independent risk factors for late-life Alzheimer disease. Ann Intern Med (2002) 2.41
Functional variants at the 11q13 risk locus for breast cancer regulate cyclin D1 expression through long-range enhancers. Am J Hum Genet (2013) 2.24
Mitochondrial DNA polymerase W748S mutation: a common cause of autosomal recessive ataxia with ancient European origin. Am J Hum Genet (2005) 2.23
A transforming growth factorbeta1 signal peptide variant increases secretion in vitro and is associated with increased incidence of invasive breast cancer. Cancer Res (2003) 2.21
A multinational, randomised, 12-week study comparing the effects of donepezil and galantamine in patients with mild to moderate Alzheimer's disease. Int J Geriatr Psychiatry (2004) 2.21
Assessment of beta-amyloid in a frontal cortical brain biopsy specimen and by positron emission tomography with carbon 11-labeled Pittsburgh Compound B. Arch Neurol (2008) 2.19
The matrilineal ancestry of Ashkenazi Jewry: portrait of a recent founder event. Am J Hum Genet (2006) 2.18
NAD(P)H:quinone oxidoreductase 1 NQO1*2 genotype (P187S) is a strong prognostic and predictive factor in breast cancer. Nat Genet (2008) 2.18
Self-reported hearing problems among older adults: prevalence and comparison to measured hearing impairment. J Am Acad Audiol (2011) 2.17
Incidence and risk factors for mild cognitive impairment: a population-based three-year follow-up study of cognitively healthy elderly subjects. Dement Geriatr Cogn Disord (2004) 2.12
Association between mid-life marital status and cognitive function in later life: population based cohort study. BMJ (2009) 2.00
Prevalence of the primary LHON mutations in Northern Finland associated with bilateral optic atrophy and tobacco-alcohol amblyopia. Acta Ophthalmol (2012) 2.00
Mitochondrial DNA polymorphisms associated with longevity in a Finnish population. Hum Genet (2002) 2.00
CSF Abeta42, Tau and phosphorylated Tau, APOE epsilon4 allele and MCI type in progressive MCI. Neurobiol Aging (2006) 1.96
Treatment for mitochondrial disorders. Cochrane Database Syst Rev (2012) 1.94
Identification of a BRCA2-specific modifier locus at 6p24 related to breast cancer risk. PLoS Genet (2013) 1.88
The Alzheimer's Association external quality control program for cerebrospinal fluid biomarkers. Alzheimers Dement (2011) 1.87
19p13.1 is a triple-negative-specific breast cancer susceptibility locus. Cancer Res (2012) 1.81
Multi-method analysis of MRI images in early diagnostics of Alzheimer's disease. PLoS One (2011) 1.79
Increased fMRI responses during encoding in mild cognitive impairment. Neurobiol Aging (2006) 1.74
Amyloid and tau proteins in cortical brain biopsy and Alzheimer's disease. Ann Neurol (2010) 1.74
RAD50 and NBS1 are breast cancer susceptibility genes associated with genomic instability. Carcinogenesis (2006) 1.70
Using genome-wide complex trait analysis to quantify 'missing heritability' in Parkinson's disease. Hum Mol Genet (2012) 1.68
Radial width of the temporal horn: a sensitive measure in Alzheimer disease. AJNR Am J Neuroradiol (2002) 1.66
Penetrance analysis of the PALB2 c.1592delT founder mutation. Clin Cancer Res (2008) 1.65
Common breast cancer susceptibility loci are associated with triple-negative breast cancer. Cancer Res (2011) 1.65
Visual presentation of novel objects and new spatial arrangements of objects differentially activates the medial temporal lobe subareas in humans. Eur J Neurosci (2004) 1.63
Association of ESR1 gene tagging SNPs with breast cancer risk. Hum Mol Genet (2009) 1.58
Associations of common variants at 1p11.2 and 14q24.1 (RAD51L1) with breast cancer risk and heterogeneity by tumor subtype: findings from the Breast Cancer Association Consortium. Hum Mol Genet (2011) 1.56
The co-occurrence of mtDNA mutations on different oxidative phosphorylation subunits, not detected by haplogroup analysis, affects human longevity and is population specific. Aging Cell (2013) 1.56
Evidence of gene-environment interactions between common breast cancer susceptibility loci and established environmental risk factors. PLoS Genet (2013) 1.56
Incidence of stroke in people with Alzheimer disease: a national register-based approach. Neurology (2013) 1.55
Neuropathologic features of frontotemporal lobar degeneration with ubiquitin-positive inclusions visualized with ubiquitin-binding protein p62 immunohistochemistry. J Neuropathol Exp Neurol (2008) 1.55
Frontotemporal dementia as a neural system disease. Neurobiol Aging (2005) 1.55
A comparison between the accuracy of voxel-based morphometry and hippocampal volumetry in Alzheimer's disease. J Magn Reson Imaging (2004) 1.54
Mitochondrial DNA and ACTN3 genotypes in Finnish elite endurance and sprint athletes. Eur J Hum Genet (2005) 1.54
Levels of mTOR and its downstream targets 4E-BP1, eEF2, and eEF2 kinase in relationships with tau in Alzheimer's disease brain. FEBS J (2005) 1.54
Diffusion tensor imaging and tract-based spatial statistics in Alzheimer's disease and mild cognitive impairment. Neurobiol Aging (2009) 1.53
iTRAQ and multiple reaction monitoring as proteomic tools for biomarker search in cerebrospinal fluid of patients with Parkinson's disease dementia. Exp Neurol (2012) 1.52
Assessing interactions between the associations of common genetic susceptibility variants, reproductive history and body mass index with breast cancer risk in the breast cancer association consortium: a combined case-control study. Breast Cancer Res (2010) 1.51
Alcohol drinking in middle age and subsequent risk of mild cognitive impairment and dementia in old age: a prospective population based study. BMJ (2004) 1.51
Fat intake at midlife and cognitive impairment later in life: a population-based CAIDE study. Int J Geriatr Psychiatry (2008) 1.49
Genotype-phenotype analysis in patients with giant axonal neuropathy (GAN). Neuromuscul Disord (2007) 1.49
Acute liver failure after valproate exposure in patients with POLG1 mutations and the prognosis after liver transplantation. Liver Transpl (2014) 1.48
Determinants of costs of care for patients with Alzheimer's disease. Int J Geriatr Psychiatry (2006) 1.47
CSF Abeta42 and tau or phosphorylated tau and prediction of progressive mild cognitive impairment. Neurology (2005) 1.46
Multivariate analysis of MRI data for Alzheimer's disease, mild cognitive impairment and healthy controls. Neuroimage (2010) 1.44
Midlife coffee and tea drinking and the risk of late-life dementia: a population-based CAIDE study. J Alzheimers Dis (2009) 1.43
MRI of hippocampus and entorhinal cortex in mild cognitive impairment: a follow-up study. Neurobiol Aging (2006) 1.41
[Genetics of Alzheimer's disease]. Duodecim (2004) 1.40
Fine-scale mapping of the FGFR2 breast cancer risk locus: putative functional variants differentially bind FOXA1 and E2F1. Am J Hum Genet (2013) 1.39
Mutations in STAT3 and diagnostic guidelines for hyper-IgE syndrome. J Allergy Clin Immunol (2010) 1.36
A combination of three common inherited mitochondrial DNA polymorphisms promotes longevity in Finnish and Japanese subjects. Eur J Hum Genet (2005) 1.36
The AddNeuroMed framework for multi-centre MRI assessment of Alzheimer's disease: experience from the first 24 months. Int J Geriatr Psychiatry (2011) 1.35
Patient- and proxy-reported utility in Alzheimer disease using the EuroQoL. Alzheimer Dis Assoc Disord (2006) 1.35
Transcription factors zeb1, twist and snai1 in breast carcinoma. BMC Cancer (2011) 1.35